GO
Loading...

CNBC's Dan Scott: Novartis Drug Galvus Could be Delayed

Swiss pharmaceutical giant Novartis' plans to launch diabetes treatment Galvus may be dealt a blow by the Food and Drug Administration at the end of the month, market sources told CNBC Europe.

The FDA will ask for more clinical data on the 100 mg dose of Galvus, expected to be a blockbuster drug with sales of more than $1 billion, CNBC Europe's Dan Scott reported. Only the 50 mg dose will be allowed to market.

If the FDA does proceed in that fashion "it would basically mean that there's not much sense in launching this drug in 2007, or rather until there is an OK for both applications," Scott said.

If that happens, the entire analysts' community will have to change earnings forecasts for the company, due to a major delay in expected revenues, he added.

Galvus approval was already delayed by regulators' requests for more data in November.

Shares of Novartis, already down recently on analyst speculation of a delay, fell a further 1%.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    To learn more about how we use your information,
    please read our Privacy Policy.
    › Learn More

Don't Miss

U.S. Video

  • This video is 90 seconds of cyber attacks happening around the globe, courtesy of Norse Norse is a technology company that bills itself as the "global leader in live attack intelligence." The company offers continuously "updated and unique Internet and darknet intel that helps organizations detect and block attacks that other systems miss."

  • Is this breakout story on your radar? Mad Money host Jim Cramer is about to put it there.

  • Paul Hickey, Bespoke Investment co-founder, discusses the huge divergence between the S&P 500 and the energy sector.